Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of 64CuCl2 PET/CT in urologic tumors
2017-000940-17Phase 2Terminated
- Start
- Jan 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copper-64 chloride in genitourinary cancer. Primary endpoint: Patient-based sensitivity and safety of 64CuCl2 PET/CT. Started Jan 2018; status: terminated.
02
Drugs
copper-64 chloride
03
Conditions
genitourinary cancer
Beyond the preview
Go deeper on 2017-000940-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000940-17.